Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

[1]  Marta Pereira,et al.  Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal. , 2019, European journal of cancer care.

[2]  Nofisat Ismaila,et al.  Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  F. Bonnetain,et al.  Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France. , 2019, Clinical lymphoma, myeloma & leukemia.

[4]  Jesús Martín Sánchez,et al.  Multiple Myeloma Treatment in Real‐world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study , 2018, Clinical lymphoma, myeloma & leukemia.

[5]  R. Hájek,et al.  Real‐world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies , 2018, Clinical lymphoma, myeloma & leukemia.

[6]  K. Batt,et al.  Economic burden of multiple myeloma among patients in successive lines of therapy in the United States , 2018, Leukemia & lymphoma.

[7]  H. Leleu,et al.  Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy , 2018, Journal of medical economics.

[8]  H. Goldschmidt,et al.  Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  C. Hofmeister,et al.  Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  H. Goldschmidt,et al.  Diagnostic and therapeutic approaches to multiple myeloma patients: ‘Real-world’ data from representative multicentre treatment surveys in Germany between 2008 and 2011 , 2016, Oncology letters.

[11]  M. Mehra,et al.  Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD. , 2016, The oncologist.

[12]  M. Delforge,et al.  Multiple myeloma: practice patterns across Europe , 2016, British journal of haematology.

[13]  M. Delforge,et al.  Multiple myeloma: patient outcomes in real‐world practice , 2016, British journal of haematology.

[14]  T. Flaig,et al.  Treatment evolution for metastatic castration‐resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real‐world data , 2015, Cancer medicine.

[15]  R. Potluri,et al.  Characterization of Treatment Resistant Depression Episodes in a Cohort of Patients from a US Commercial Claims Database , 2013, PloS one.

[16]  G. Morgan,et al.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.

[17]  Dr H. Oakervee.  Myeloma , 2002, Lyon medical.

[18]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[19]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[20]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[21]  K. Fushimi,et al.  Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. , 2011, American journal of epidemiology.